We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Blood Test Advances Diagnosis Of HELLP Syndrome

By LabMedica International staff writers
Posted on 01 Jun 2016
A laboratory blood test for the diagnosis of a rare genetic red blood cell disorder also shows promise in identifying HELLP syndrome, a life-threatening high blood pressure condition affecting 1% of all pregnant women.

HELLP is an acronym for hemolysis, elevated liver enzymes and low platelets and is a severe variant of pre-eclampsia whose pathogenesis remains unclear. More...
Recent evidence and clinical similarities suggest a link to atypical hemolytic uremic syndrome, a disease of excessive activation of the alternative complement.

Scientists at Johns Hopkins University School of Medicine (Baltimore, MD, USA) used the modified Ham test to study serum samples from 14 women with classic or atypical HELLP syndrome, seven women with severe preeclampsia, 11 women with normal pregnancies, and eight healthy non-pregnant women. All pregnant women were at least 23 weeks pregnant.

Serum Complement C5b-9 Membrane Attack Complex levels were determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Quidel, San Diego, CA, USA). The modified Ham test reflects complement activation as a percentage of complement-mediated cell-killing and is thereby a functional assay. The modified Ham test was measured in an iMark Microplate Absorbance Reader (Bio-Rad, Hercules, CA, USA) at 490 nm with a reference wavelength at 595 nm.

The investigators found increased complement activation, as measured by the modified Ham test, in women with classic or atypical HELLP, compared to those with normal pregnancies or those not pregnant. They observed average cell killing of 34.3% in those with classic HELLP, and 26% in atypical HELLP compared to an average 5% in those with normal pregnancies and 3.3% in those who were not pregnant. They also found that mixing serum from women with classic or atypical HELLP together with a monoclonal antibody that blocks complement, resulted in a significant decrease in the killing of cells in the modified Ham test, from about a 34% kill rate down to a 5% kill rate, the amount seen in healthy individuals.

Arthur J. Vaught, MD, a maternal fetal medicine fellow and lead author of the study said, “The clinical implications from an obstetric point of view are potentially huge. If this works, we can reduce pre-term deliveries, stays in the neonatal intensive care unit and other complications for mothers and their babies. This assay may aid in the diagnosis of HELLP syndrome and could confirm that its pathophysiology is related to that of atypical hemolytic uremic syndrome.” The study was published in the May 2016 issue of the journal Experimental Hematology.

Related Links:
Johns Hopkins University School of Medicine
Quidel
Bio-Rad

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The automated multiplex PCR assay runs on the BioFire Spotfire Vaginitis System, bringing molecular vaginitis testing to the point of care (Photo courtesy of bioMérieux)

Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use

Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: The CE-marked software IVD combines digital histopathology and clinicopathological data to generate a prognostic classification (Image Credit: Shutterstock)

Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer

In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.